Acute Coronary Syndrome News and Research RSS Feed - Acute Coronary Syndrome News and Research

Adding ezetimibe to statin therapy reduces cardiovascular events

Adding ezetimibe to statin therapy reduces cardiovascular events

More than a decade ago, researchers from Brigham and Women's Hospital demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events. [More]
Using cardiac biomarkers to identify NSTEMI and ACS patients: an interview with Peter Mason

Using cardiac biomarkers to identify NSTEMI and ACS patients: an interview with Peter Mason

ACS is currently identified through the use of ECGs pre-hospital and the confirmed via a Troponin biomarker test once in the acute setting. [More]
Studies evaluate traditional management of heart attack patients after discharge from hospital

Studies evaluate traditional management of heart attack patients after discharge from hospital

Beta-blockers have been a cornerstone in the treatment of heart attack survivors for more than a quarter of a century. However, many of the data predate contemporary medical therapy such as reperfusion, statins, and antiplatelet agents, and recent data have called the role of beta-blockers into question. [More]
Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Cardiome Pharma Corp. today announced results from a Phase 3 clinical study conducted with BRINAVESS (vernakalant intravenous, RSD 1235) in the Asia-Pacific (A-P) region. [More]
First-ever evidence-based guidelines released for prevention of acute COPD exacerbations

First-ever evidence-based guidelines released for prevention of acute COPD exacerbations

The American College of Chest Physicians (CHEST) and the Canadian Thoracic Society (CTS) announced today the release of Prevention of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: American College of Chest Physicians and Canadian Thoracic Society Guideline in the journal CHEST. [More]
Darapladib drug fails to reduce risk of recurrent major coronary events

Darapladib drug fails to reduce risk of recurrent major coronary events

In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable angina), use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 (believed to play a role in the development of atherosclerosis) did not reduce the risk of recurrent major coronary events, according to a study published by JAMA. [More]
Study: Resistant hypertension increases risk of stroke in female and elderly patients

Study: Resistant hypertension increases risk of stroke in female and elderly patients

Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress today by Dr Kuo-Yang Wang from Taiwan. [More]
Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations. [More]
Cardiome Pharma reports record revenues in second quarter 2014

Cardiome Pharma reports record revenues in second quarter 2014

Cardiome Pharma Corp. today reported financial results for the second quarter and six months ended June 30, 2014. [More]
EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone). [More]
New study explores relationship between personality and heart attacks

New study explores relationship between personality and heart attacks

A new study published in the current issue of Psychotherapy and Psychosomatics has addressed the relationship between personality and heart attacks. [More]
Findings shed light on possible role of affective temperaments in cardiovascular morbidity

Findings shed light on possible role of affective temperaments in cardiovascular morbidity

Temperament has been traditionally associated with high blood pressure. A new study that has appeared in the current issue of Psychotherapy and Psychosomatics has substantiated this issue. [More]
Researchers use simple tactics to reduce unnecessary blood tests, health care spending

Researchers use simple tactics to reduce unnecessary blood tests, health care spending

Researchers at Johns Hopkins Bayview Medical Center used two relatively simple tactics to significantly reduce the number of unnecessary blood tests to assess symptoms of heart attack and chest pain and to achieve a large decrease in patient charges. [More]
iGetBetter selects Validic platform to access data from broad range of biometric devices

iGetBetter selects Validic platform to access data from broad range of biometric devices

iGetBetter, Inc., a supplier of post-acute care transition solutions, and Validic, the healthcare industry's premier technology platform for accessing digital health data, announced today that iGetBetter has selected the Validic platform to access data from a broad range of available biometric devices as part of its care transition solution focused on reducing readmissions. [More]
Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate. [More]
Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda to present results from global EXAMINE CV safety outcomes trial at ACC 2014

Takeda Pharmaceuticals Company Limited will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, DC. [More]
Study: Men are more likely to receive faster care for heart attacks and angina than women

Study: Men are more likely to receive faster care for heart attacks and angina than women

A new study indicates that in younger adults experiencing heart attacks and angina, men are more likely to receive faster care compared with women. The study, published in CMAJ (Canadian Medical Association Journal) also found that gender-related factors affected access to care for both men and women. [More]
Outbursts of anger may trigger heart attacks and strokes, shows study

Outbursts of anger may trigger heart attacks and strokes, shows study

Outbursts of anger may trigger heart attacks, strokes and other cardiovascular problems in the two hours immediately afterwards, according to the first study to systematically evaluate previous research into the link between the extreme emotion and all cardiovascular outcomes. [More]
Angry outbursts increase heart attack risk

Angry outbursts increase heart attack risk

Call it what you will - getting red in the face, hot under the collar, losing your cool, blowing your top - we all experience anger. And while we know that anger is a normal, sometimes even beneficial emotion, we're also aware of the often harmful connection between anger and health. New research from Beth Israel Deaconess Medical shows an even more compelling reason to think about getting anger in check - a nearly fivefold increase in risk for heart attack in the two hours following outbursts of anger. [More]
Patients with dental extractions before cardiac surgery still at risk for poor outcomes

Patients with dental extractions before cardiac surgery still at risk for poor outcomes

To pull or not to pull? That is a common question when patients have the potentially dangerous combination of abscessed or infected teeth and the need for heart surgery. [More]